Cosmobeauté Indonesia 2019 Helps Raise Locally Made and Eco-Friendly Beauty Products
Mitsubishi Electric to Exhibit Autonomous-driving Technologies Incorporated in New xAUTO Test Vehicle
Cell Signaling Technology and Cell Press Launch Cell Mentor in China
Japan's First! Japanese Real Estate Developer Lead Real Estate Condominium and Hotel Development Through STO Fund
Putting Prevention First, ORENDA Initiates Health Promotion Inspired by Traditional Chinese Culture
D+29 Launches on Korea GSL Bio's Online Store to Provide "30 Seconds of Natural Cleansing"
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Adva
Liquefy partners with a consortium of Gulf families to digitize property assets for over US$ 1 billion, starting with a landmark Mayfair luxury hotel
Cubic Showcases Intelligent Transport Management Technologies at ITS World Congress in Singapore
Berkshire Hathaway Specialty Insurance Expands Surety Business, Appoints Jonathan Griffiths Head of Surety in Australia
-
New subcutaneous formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) shows positive Phase 1 results for the treatment of IBD in data
Results from a multicentre, open-label, randomised Phase 1, pivotal study showed that the subcutaneous (SC) formulation of CT-P13 (biosimilar infliximab) was non-inferior to intravenous (IV) formulation of CT-P13 in terms of pharmacokinetics in inflammatory bowel disease patients at week 22 CT-P13 SC also showed comparable efficacy and safety to CT-P13 IV for patients with Crohn’s disease (CD) and ulcerative colitis (UC) up to week 30 Novel subcutaneous formulation could provide an alternative administration option for physicians and their patients BARCELONA, Spain--(BUSINESS WIRE)--Celltrion Healthcare today announced new data from a Phase 1 pivotal study to evaluate the pharmacokinetics (PK), efficacy and safety of CT-P13 SC compared to the CT-P13 IV formulation in people with inflammatory bowel disease (IBD). Results presented at UEG Week 2019 in Barcelona, Spain demonstrated non-inferiority of CT-P13 SC compared to CT-P13 IV in the PK primary endpoint at pre-dose level (Ctrough) at week 22, and in the secondary endpoints efficacy and safety up to week 30. In the study, 136 patients were enrolled and 131 were randomised (66 to CT-P13 SC and 65 to CT-P13 IV). After loading doses of IV 5mg/kg at weeks 0 and 2, patients were randomised at week 6 to receive either CT-P13 SC 120mg (<80kg) or 240mg (≥80kg) every 2 weeks in the CT-P13 SC arm, or CT-P13 IV 5mg/kg every 8 weeks in the CT-P13 IV arm. The Phase 1 pivotal study demonstrated that CT-P13 SC showed non-inferiority in PK to CT-P13 IV as determined by the trough concentration, pre-dose level (Ctrough) at week 22. In terms of efficacy, both clinical response and remission in patients were induced and maintained, and the overall efficacy results of CT-P13 SC were comparable. The combined clinical remission rates for CD and UC patients at week 30 were comparable between CT-P13 IV and CT-P13 SC (66.7%, 44 out of 66 patients in CT-P13 SC arm and 54.7%, 35 out of 64 patients in CT-P13 IV, p=0.1620). The safety profile of CT-P13 SC was comparable to CT-P13 IV. In addition, fewer patients were found to have positive anti-drug-antibodies with CT-P13 SC compared to CT-P13 IV. A subcutaneous formulation of CT-P13 has the potential to enhance treatment options for the use of biosimilar infliximab by providing high consistency in drug exposure and a convenient method of administration. “CT-P13, a biosimilar of infliximab, has already been thoroughly characterized as a prime choice for intravenous infliximab therapy in t he past with dedicated trials demonstrating clinical similarity in comparison with the originator molecule in both RA and IBD. The new, highly innovative SC formulation of infliximab has been specifically developed to address unmet needs in maintenance therapy. Our results from the ongoing development program for SC CT-P13 infliximab are promising. CT-P13 SC infliximab has the potential to become the most innovative biosimilar treatment – improving convenience and allowing patients to have more control of their treatment in addition to direct clinical benefits,” said Professor Stefan Schreiber, Director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany and first author of the study. “Not without reason the IV/SC sequence therapy that has been implemented into most development paths for novel molecules.” “A new subcutaneous formulation of infliximab has the potential to change the way patients manage their condition on a day-to-day basis, offering them greater choice and convenience in the long term. Furthermore, offering patients the option to self-administer will reduce demand on healthcare systems, by lessening patient time spent in hospitals, keeping patients out of clinics and providing clinicians with additional time to spend with other patients,” said Mr. Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. “This new formulation could create a new treatment paradigm with IV/SC sequence therapy making treatment affordable, convenient and personalised.” Celltrion seeks approval for the inflammatory bowel disease (IBD) indication for CT-P13 SC in the second half of 2020. --- ENDS --- Notes to editors: About inflammatory bowel disease Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life.1 They affect an estimated 5 million people globally;2 IBDs account for substantial costs to the healthcare system and society; the direct healthcare costs of IBDs are estimated to be €4.6-5.6 billion per year.3 About CT-P13 (biosimilar infliximab) CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 89 countries (as of October 2019) including the US, Canada, Japan and throughout Europe. About Celltrion Healthcare Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/ References 1 Molodecky, N. A, et al. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142(1), 46-54. Retrieved from: www.gastrojournal.org/article/S0016-5085 (11)01378-3/pdf [Last accessed October 2019]. 2 The European Federation of Crohn’s & Ulcerative Colitis Associations. (n.d). What is IBD? Science Retrieved from www.efcca.org/en/science [Last accessed October 2019]. 3 Burisch, J, et al. (2013). The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis, 7(4), 322-337.Retrived from: https://www.sciencedirect.com/science/article/pii/S1873994613000305?via%3Dihub [Last accessed October 2019]. Contacts Preetika Ramjoorawon pramjoorawon@hanovercomms.com+44 203 817 6718 Sophia Eminson seminson@hanovercomms.com+44 203 817 6583
-
ADX Group Announces IPO Progress, New Cyber Security Offerings
JEJU ISLAND, South Korea--(BUSINESS WIRE)--ADX Group (“ADX”), owner and operator of online business services, online entertainment, and consumer electronics, announced today that the company’s progress towards its initial public offering (IPO) has advanced. In comments the day before the company’s 11th annual Autumn Conference, ADX Founder Mr. Steven M. Renner said, “ADX has formally engaged independent auditors to commence a pre-IPO audit, and our NASDAQ IPO remains on track for early 2022.” Attending the conference on Jeju Island, South Korea, more than 700 ADX sales consultants heard updates on the company’s IPO, new ADX Cyber Security Services (including ADX Mail, ADX Cloud, ADX VPN, and WebCast.Pro secure conferencing services), YouChat secure mobile messaging services, popular AWL Cloud Hosting Services, and advances in ADX Mobile Games. “The focus of our 11th Autumn conference is ADX Cyber Security Services,” said Renner. “ADX’s advances in artificial intelligence, machine learning, deep learning, and blockchain technology as a service have significantly enhanced ADX’s AWL Cloud Services end-user accounts. Building upon AWL’s momentum, ADX Cyber Security Services enables simple and effective safeguarding of individual freedoms and privacy, which are increasingly under threat.” About ADX Group ADX Group is a global technology company which creates and sells ADX-branded online web and mobile business services, online entertainment, and consumer electronics to more than 500,000 customers in partnership with 100,000+ active distributors in 120+ countries. ADX’s mission is “Changing People’s Lives through the Power of Technology.” ADX’s portfolio of online business services includes AWL Cloud Services, an all-in-one online business platform augmenting hosting technology with advanced AI, machine learning, deep learning, and blockchain management; ADX Cyber Security Services; ADX Discover, which carries thousands of consumer classified ads across 19 categories; aPay mobile payment platform (in partnership with aPay Systems, Malta); WebCast Pro secure, multilingual webcasting; Shop.Pro and the iRewards Shop multilingual eCommerce platforms; AppMart Pro “build-it-for-me" and DIY app development platform, with more than 870,000 mobile apps built; ADX Mail secure online email service; VideoMeet Pro live video broadcasting and conferencing; and YouChat, a mobile text, photo and video messaging app. ADX’s online entertainment portfolio includes the aSports roster of interactive social games, including the popular aDowns horse racing and dog racing games; dozens of GameSmart casual online games which have recently been conveniently built into the ADX aSports mobile app; and 18 Youle888 Chinese language games. ADX consumer electronics include advanced smartphones and accessories, tablets, high-end wireless audio devices, and smartwatches coupled with the aHEALTH online service, all of which are marketed on ADX’s Mobile.Net platform and via 100,000+ active distributors in 120+ countries. For more information on ADX Group and ADX, please download our media backgrounder kit (English and Chinese versions included): http://bit.ly/adxmediakit2 and visit the ADX website http://adxsales.com This media release is for informational purposes only and is not an offer to sell or a solicitation of an offer to purchase. "Safe Harbor" Statement This media release contains forward-looking statements that involve risks and uncertainties that could affect the actual future results and the transactions referred to in the text. These risks and uncertainties include, but are not limited to: ADX’s ability to continue to attract, retain and motivate its distributors, regulatory changes affecting sales through direct marketing networks of electronics, online entertainment and online business services, the volatility of ADX’s profits, the acceptance of direct marketing by consumers, the economic conditions in the countries where ADX operates, the presence of potential competitors, negative publicity, cultural factors or local demographics. Contacts Simon Cousins, +1 347 850-3360 (Media) Richard Cant, +1 612 460-4700 (Investors)
-
Aryaka Names Mario Vecchio Senior Vice President, Asia Pacific
Newest Addition to Aryaka’s Leadership Team to Drive the Company’s Expansion in the Region SAN MATEO, Calif.--(BUSINESS WIRE)--Aryaka®, the #1 end-to-end managed SD-WAN provider, announced today the appointment of Mario Vecchio as Aryaka’s senior vice president of APAC. In his new role, Mario will lead Aryaka’s push into the Asia-Pacific (APAC) region as the company continues to accelerate WAN transformation initiatives and expand its global footprint in the coming year. Mario has a proven track record of delivering impressive revenue gains, profit growth and market share increases through his strategic sales leadership. He has more than 25 years of experience in the region where he has focused on direct and indirect sales for complex managed IT service and networking organizations. Effective immediately, Mario is charged with scaling the company’s presence across the APAC region, enhancing the structure of the Aryaka global partner program, improving partner enablement and overseeing recruitment. “As the newest addition to our robust leadership team, Mario will play a critical role in growing Aryaka’s business,” said Karen Freitag, Chief Revenue Officer at Aryaka. “Our strategy is to accelerate our growth in the APAC region, and we will do that through our strategic partnerships and Mario’s unmatched experience in the managed services and networking industries.” Prior to joining Aryaka, Mario was senior vice president of APAC at Big Switch Networks where he led the growth and success of the sales organization and its go-to-market strategy. Under his leadership, Big Switch saw its revenue increase over 100 percent year-over-year. Prior to Big Switch, Mario founded Progility Technologies where he served as chairman and CEO for more than seven years. At Progility, Mario grew the company to 800 employees and $180 Million in revenue with more than 30 offices around the globe. “Aryaka is the clear leader in the managed SD-WAN space and its technology is a game-changer for enterprises making their digital transformation journeys,” said Mario Vecchio. “I’m excited to be joining the company at such a pivotal stage in Aryaka’s evolution. I look forward to supporting and expanding our existing customer base and nurturing our essential channel partners in the region.” For more on Aryaka, please visit: https://www.aryaka.com/ Visit the Aryaka blog: https://www.aryaka.com/blog/ Follow Aryaka on Twitter: @AryakaNetworks Visit Aryaka on LinkedIn: https://www.linkedin.com/company/aryaka-networks/ About Aryaka Aryaka delivers the #1 fully managed, end-to-end global SD-WAN service for the cloud-first era. Our unique technology integrates multi-cloud connectivity, application optimization, security, last-mile management and visibility into an SLA-driven OPEX-only solution that provides unmatched agility and improved TCO for the global enterprise. Contacts US Aryaka Media Contact:Liam Collopy Executive Vice President Harden Communications Partners Ph: 510-488-2472 Lcollopy@hardenpartners.com UK Aryaka Media Contact:Elliot Harrison Account Director, Head of Digital Positive Marketing Ph: +44 (0)20 3637 0649 M: +44 (0)7763 683 055 E: eharrison@positivemarketing.com
-
TransPerfect Expands Media Localization Group With Acquisition of Sublime Subtitling and Translation
Madrid-Based Subtitling Specialist Joins World’s Largest Translation and Localization Company NEW YORK & MADRID--(BUSINESS WIRE)--TransPerfect, the world’s largest provider of language and technology solutions for global business, today announced the acquisition of Sublime Subtitling & Translation. Financial terms of the agreement were not disclosed. Founded in Madrid in 2017 by partners Sevan Bruce Nazarian, Marta Román, Iván Poveda, and Luisana León, Sublime specializes in audiovisual translation and subtitling for global entertainment clients. TransPerfect has grown rapidly in the media space, including recently announced deals to acquire Lylo, Lassostudios, and AGM Factory. The company has invested heavily in providing the most advanced dubbing, voiceover, and subtitling services, including AI-powered solutions, to clients via its Media.NEXT technology platform. Welcoming Sublime to the TransPerfect family of companies complements its existing infrastructure—which includes TransPerfect’s Barcelona-based studios and Lassostudios’ Madrid facility. The founding partners will continue to lead the division and will join TransPerfect’s senior management team, where they will advise on overall company production strategy for media and entertainment. All current employees are expected to remain with the company, and the division will report to TransPerfect’s Senior Vice President Barnaby Wass based in Barcelona. Nazarian remarked, “By combining the know-how and expert subtitling resources of the Sublime team with the technologies and resources of the TransPerfect team, we will now be able to do what we do best on a much larger scale and in a more cost-effective manner. Together, we are better equipped to meet the challenges of our growing industry and offer our clients the best possible solutions.” TransPerfect President and CEO Phil Shawe stated, “Sublime is a fresh and dynamic agency that has quickly grown into a respected player in media localization. We’re delighted to welcome their team to our family of companies.” About Sublime Sublime is a boutique media localization agency based in Spain, made up of young and passionate industry experts offering a wide range of end-to-end localization services with an ISO 9001 certified process across 35 languages to key actors of the media industry. Our mission is to bridge human beings by breaking through language and cultural barriers. For more information, visit www.sublimesubtitling.com. About TransPerfect TransPerfect is the world’s largest provider of language and technology solutions for global business. From offices in over 90 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 5,000 global organizations employ TransPerfect’s GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com. Contacts Ryan Simper +1 212.689.5555mediainquiry@transperfect.com
-
2019 World Conference on VR Industry held in Nanchang, China
Nanchang, China, Oct 21, 2019 - (ACN Newswire) - The 2019 World Conference on VR Industry (WCVRI 2019), co-hosted by the Ministry of Industry and Information Technology (MIIT) and Jiangxi Provincial People's Government, is being held in Nanchang, Jiangxi Province, from October 19th to 21st. WCVRI 2019 is seizing the opportunity at this initial stage of 5G commercialization to launch discussions on how VR (virtual reality) will support more extensive application scenarios and be empowered by more stable technologies with a theme of "VR Adorns the World - VR + 5G for A New Era of Perception".The Conference has attracted experts, scholars and company leaders from over 30 countries, including the US, Germany, Britain, Russia, India and Israel, discussing the development and application of VR, especially as 5G, the next generation mobile network, unlocks the potential of VR. With a focus on the new era of perception enabled by 5G, this year's conference is showcasing leading-edge VR technologies and the latest outcomes of the global VR industry.Miao Wei, head of the Ministry of Industry and Information Technology, the country's top industry regulator, said in the opening address that with China officially granting 5G commercial licenses on June 6, the co-development of VR and 5G promises a huge market in future. "China takes the lead in VR innovations. And the wide popularity of high-tech in our country guarantees the potential of this market," said Miao. Guo Ping, rotating chairman of Huawei, said the high-tech of VR offers a tailored, immersive experience for users, especially the younger generation who grow up with "screens". He added that VR will replace screens in the coming future. Huawei is displaying its VR glass at this year's World VR Expo - the 2019 VR/AR Products and Applications Exhibition - held in conjunction with the VR Conference, and this year attracting more than 2,000 companies from across the globe.Nanchang, which brands itself as China's VR hub, started scaling its VR industry in 2016. The city has a spacious VR industrial base, with a VR theme park to offer visitors immersive experiences, a VR exhibition center to show latest developments, a VR innovation center to gather top experts and a VR cloud center to provide cloud computing services, a necessity for VR. Companies with research or innovation centers in Nanchang include Huawei, China's e-commerce giant Alibaba, Microsoft and HTC.Hu Xiang, director of the VR center of Beijing Institute of Technology, located in Nanchang's VR industrial center, said that the wide application of 5G will enable VR technology to influence people's lives, much as the smartphone did. Hu's center set up an installation at the VR Expo equipped with high-resolution cameras, producing virtual individuals when people in the 'center' have data collected. "Once 5G is widely applied, our project of virtual humans will develop quickly," added Hu.Liu Qi, Party Secretary of Jiangxi, said videos prevail in the era of 4G, while VR will gain traction in the 5G era. "The high-tech of VR will be the first application frontier of 5G. The spring for VR is coming", said Liu. According to local government, 108 VR-related projects have been inked since last year, with total investment of RMB 35.1 billion (US$ 4.9 billion). Last year's VR output in Jiangxi, together with Internet of Things, surpassed RMB 50 billion. The government estimates that by 2023, the annual output will surpass RMB 100 billion. As the VR industry matures by further expanding into the consumer and enterprise markets and improving its value chain, 5G commercialization will fundamentally improve the VR experience and create new opportunities for the application of VR technologies. With rapid development of the VR value chain, including hardware manufacturing, R&D of content-driven applications, and experience-based service promotion, China is building its VR industry into one with the most dynamic environments for innovation and entrepreneurship, highest market acceptance, and the greatest growth potential in the world. Visit the 2019 World Conference on VR Industry at http://www.wcvri.cn/indexen, or contact Jan Zhang at contact3@wcvri.cn. Copyright 2019 ACN Newswire. All rights reserved. www.acnnewswire.com
-
Mastercard Expands Bill Pay Exchange Partners
PURCHASE, N.Y.--(BUSINESS WIRE)--Mastercard today announced that it is working with several new partners, including ConEd, to roll out Mastercard Bill Pay Exchange. Avidia Bank, Aliaswire Inc., OSG Billing Services and Transactis will be among the first to offer Bill Pay Exchange to their customers. Mastercard rolled out Bill Pay Exchange to make it easier for consumers to view, manage and pay telecom, utility, rent, credit card, mortgage and other personal bills without having to set up accounts with different billers, remember multiple passwords, and log in to multiple websites. With Bill Pay Exchange, consumers can pay their bills either with cards, real-time payments or from their bank account, and receive confirmation of payment all within their banking app or website. This solution will give billers access to a new billing and payment channel, which can reduce the cost of mailing paper bills and processing checks, provide streamlined reconciliation and lower customer support costs due to added payment transparency. Billers will also have the option to accept cards, real-time payments, or traditional bank account payments as they do on their own websites. “ConEd is committed to continuously improving our billing and payment options for our customers,” said Frank D’Amadeo, director of Treasury at ConEd. “By delivering bills directly to our customers’ banks, they have a new option to simplify how they can see and pay their bills.” Mastercard will also be testing the solution with eight other partners, including Best Digital Solutions, Inlet, Nordis Technologies, Papaya, Payrailz, Plastiq, RR Donnelley (RRD), and Synapse to make the solution available for consumers. These partners collectively will help drive adoption and scale for the solution in the United States. “We’re excited to be partnering with Mastercard on the Bill Pay Exchange, as the solution aligns perfectly with our transformative approach to customer communications,” said Jonathan Gustave, Executive Vice President of OSG Billing Services. “Since first announcing Bill Pay Exchange, Mastercard has continued to evolve this digital solution to benefit consumers, billers and financial institutions alike,” said Ronald Shultz, executive vice president, New Payment Flows, North America, Mastercard. “With the help of our trusted pilot partners, this solution will bring speed, transparency and efficiency to bill payments for the masses.” QUOTE SHEET: "We are thrilled to bring our comprehensive content management capabilities and strong client relationships to our partnership with Bill Pay Exchange. We look forward to assisting Mastercard in its efforts to better connect with its customers through this new offering." – John Pecaric, President, RRD Business Services. “Mastercard Bill Pay Exchange brings compelling new presentment and payment experiences, including a choice of payment instruments, to Inlet’s expanding biller network while enabling improved consumer interactions at our bill pay channels.” – Christopher Johnson, CEO at Inlet. “Through our partnership with Mastercard, our biller clients can deliver their consumers a significantly improved online bank bill pay experience. The Bill Pay Exchange is a perfect fit for our strategy to offer innovative billing and payment options to our customers. This product is a game changer for online bill pay and we are excited to be a part of it.” – Ronnie Selinger, President/CEO Nordis Technologies. “With Bill Pay Exchange, Mastercard is leading the industry with an innovative approach to improving the bill payment user experience and transforming the relationship between billers and their financial institutions. Aliaswire is excited to participate as one of the initial partners” – Scott Goldthwaite, President, Aliaswire, Inc. About Mastercard Mastercard (NYSE: MA), www.mastercard.com, is a technology company in the global payments industry. Our global payments processing network connects consumers, financial institutions, merchants, governments and businesses in more than 210 countries and territories. Mastercard products and solutions make everyday commerce activities – such as shopping, traveling, running a business and managing finances – easier, more secure and more efficient for everyone. Follow us on Twitter @MastercardNews, join the discussion on the Beyond the Transaction Blog and subscribe for the latest news on the Engagement Bureau. Contacts Mastercard CommunicationsChaiti Sen Email: chaiti.sen@mastercard.comTel: 914.263.6542
-
Abu Dhabi Pearl: The World’s Oldest Known Natural Pearl Discovered on Marawah Island
The 8,000-year-old Pearl to be displayed for the first time at Louvre Abu Dhabi ABU DHABI, United Arab Emirates--(BUSINESS WIRE)--The oldest known natural pearl in the world has been discovered by Department of Culture and Tourism – Abu Dhabi (DCT Abu Dhabi) archaeologists working at a Neolithic site on Marawah Island, just off the coast of Abu Dhabi. Dubbed the ‘Abu Dhabi Pearl’, it was found in layers carbon dated to 5800-5600 BCE, during the Neolithic period. The discovery is proof that pearls and oysters were used in the UAE nearly 8,000 years ago, and represents the earliest known evidence for pearling yet discovered in the world. Pearls were precious elements during the Neolithic period, certainly falling into the category of luxury and used for adornment. As such, the priceless and historically significant Abu Dhabi Pearl will feature in the upcoming Louvre Abu Dhabi exhibition 10,000 Years of Luxury, where it will be on display to the public for the very first time since its discovery. Carbon dating has proven the Abu Dhabi Pearl to be older than both of the two most significant prior pearl discoveries - one uncovered at a Neolithic site in Umm al-Quwain and the other at a Neolithic cemetery in Sharjah. The Marawah site was first discovered in 1992, and consists of numerous collapsed Neolithic stone structures. Other significant finds from the site have included an imported ceramic vase, flint arrowheads and shell and stone beads. Numerous painted plaster vessel fragments discovered represent the earliest known decorative art found in the UAE. At the beginning of 2020 a major new excavation will take place at the site. Experts have suggested pearls were possibly traded with Mesopotamia in exchange for highly-decorated ceramics and other goods. Pearls were precious elements during the Neolithic period and likely worn as jewellery by the local population. The art of pearling required an in-depth knowledge of pearl beds and their locations and expert seafaring skills. Once these were mastered by the ancient inhabitants of Marawah, pearling was to remain a mainstay of the UAE’s economy for millennia. The Pearl will be featured in 10,000 Years of Luxury exhibition, taking place at Louvre Abu Dhabi from 30 October 2019 to 18 February 2020. *Source: AETOSWire Contacts Shaimaa El Nazer DCT-AbuDhabi@fourcommunications.com
-
Rosen, a Leading Law Firm, Reminds Covetrus, Inc. Investors of Important Deadline in Securities Class Action – CVET
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Covetrus, Inc. (NASDAQ:CVET) from February 8, 2019 through August 12, 2019, inclusive (the “Class Period”) of the important November 29, 2019 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Covetrus’ investors under the federal securities laws. To join the Covetrus class action, go to http://www.rosenlegal.com/cases-register-1688.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants’ statements were materially false and misleading. Specifically, defendants’ representations to investors: (1) overstated Covetrus’ capabilities with regard to inventory management and supply chain services; (2) understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs; (3) understated Covetrus’ separation costs from Henry Schein; (4) understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company’s separation from Henry Schein; and (5) as a result, Covetrus’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 29, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1688.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome. Contacts Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.compkim@rosenlegal.comcases@rosenlegal.comwww.rosenlegal.com
-
Lazard Announces Matthieu Pigasse Resignation
NEW YORK--(BUSINESS WIRE)--Lazard Ltd (NYSE: LAZ) today announced that Matthieu Pigasse, Deputy CEO of Financial Advisory and Chairman and CEO of Lazard France, has resigned from Lazard. His resignation will be effective December 31, 2019. Lazard will announce a new leadership team in France shortly. “Lazard has been my home for nearly two decades. I’ve enjoyed working with the best investment bankers and advisors in the industry, and many of the world’s most important corporate and sovereign leaders,” said Mr. Pigasse. “I am proud of what I have accomplished with my colleagues in France. Lazard in France has an unsurpassed franchise, with strong momentum. I am excited to begin my next chapter beyond investment banking in a new entrepreneurial project.” “I admire and respect Matthieu Pigasse for all he has done for our clients and our global franchise. Through his passion, intensity and commitment to excellence, Lazard has assembled a team of extremely talented bankers, and has built the best global investment banking business in France,” said Kenneth M. Jacobs, Chairman and CEO of Lazard. “Matthieu has unfortunately decided to resign, and I want to thank him for his contribution and wish him every success as he turns to his new entrepreneurial endeavor. Lazard Paris is a cornerstone of our global network, and we look forward to continuing to serve corporate leaders in France, and sovereigns globally, with the best advice in the industry.” About Lazard Lazard, one of the world's preeminent financial advisory and asset management firms, operates from 43 cities across 27 countries in North America, Europe, Asia, Australia, Central and South America. With origins dating to 1848, the firm provides advice on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services to corporations, partnerships, institutions, governments and individuals. For more information on Lazard, please visit www.lazard.com. Follow Lazard at @Lazard. LAZ-FAPE Contacts Media:Judi Frost Mackey, +1 212 632 1428 judi.mackey@lazard.com Victoire Grux, +33 1 44 13 05 8 victoire.grux@lazard.com Investors:Alexandra Deignan, +1 212 632 6886 alexandra.deignan@lazard.com
-
Rosen, a Leading Law Firm, Reminds ADTRAN, Inc. Investors of Important Deadline in Securities Class Action – ADTN
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ADTRAN, Inc. (NASDAQ: ADTN) from February 28, 2019 through October 9, 2019, inclusive (the “Class Period”) of the important December 16, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for ADTRAN investors under the federal securities laws. To join the ADTRAN class action, go to http://www.rosenlegal.com/cases-register-1692.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) there were material weaknesses in the Company’s internal control over financial reporting; (2) as a result, certain E&O reserves had been improperly reported; (3) as a result, the Company’s financial results for certain periods were misstated; (4) there would be a pause in shipments to the Company’s Latin American customer; and (5) as a result, ADTRAN’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 16, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1692.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome. Contacts Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.compkim@rosenlegal.comcases@rosenlegal.comwww.rosenlegal.com
-
Milacron Partners with ei3 to Add Unique AI Capabilities to Its “M-Powered” IoT Solution
CINCINNATI--(BUSINESS WIRE)--#K2019--Milacron Holdings Corp. (NYSE: MCRN), a leading industrial technology company serving the plastics processing industry is announcing triple digit growth since 2017, fueled through innovative products and the digital solution “M-Powered” based on our partnership with ei3. M-Powered offers a full-suite of Industry 4.0 services and predictive functions that uses advanced analytics and Artificial Intelligence to capture value from machine data to improve overall machine performance, such as availability, quality, uptime and many more. ONGOING IMPROVEMENTS To match the exponential growth, Milacron is tripling its work force for its digital solutions to further monitor projects and provide proactive customer engagement. At Milacron, we believe that all manufacturers should have access to the tools to make the best production decisions. M-Powered is fully customizable, agile and flexible intelligence software, designed to be intuitively used through analytical dashboards and reports to allow manufacturers to interpret problems and uncover opportunities to make optimal business decisions. The dashboards include basic predictive, prescriptive and analytics capabilities for key Milacron machine components like Heater Bands, Hydraulic Pumps, and Feed Screws. These predictions enable service teams to turn unplanned downtime into planned downtime, to improve machine availability. EXPANDED APPLICATIONS ei3’s latest innovation in AI through its dedicated Data Science center in Zurich, Switzerland paves the way for new - applications to support preemptive part stocking modules and expanded lifetime-tracking for mold, tooling and auxiliary components. Building on these capabilities, Milacron’s M-Powered is now able to interpret the data to determine impending failures, maintenance needs, or incorrect recipe settings of the machine. Addressing those issues leads to reduced unplanned downtime, and improved OEE These features boost existing M-Powered capabilities, valued by countless customers in everyday operations. Key Production Reporting features: Real-time reporting of production information Integrates work orders, production orders, quality, downtime and process parameter results User configuration tools Automatic scheduled email delivery of configured reports to users and groups Variety of formats including pdf, excel and text Many standard reports available Custom reports can be created upon request ei3 makes it incredibly easy to reap immediate benefits from your data set. Without much learning, investments, or waiting or large sets of data to collect, at a click of a button you can unlock ei3’s extensive production reporting capabilities. Comprehensive reports give you information on the status of your operations, allowing you to see what is going on at an unprecedented level of clarity, and take decisions based on facts and figures rather than hear-say. Each report can of course be adapted to fit your needs, both from a content perspective but also graphically (for example, it will come with your company logo on!), or you can define an entirely new report template. Reports can be browsed in HTML format on-line, sent automatically on a regular basis (daily, weekly, quarterly, yearly), or created when specific conditions warrant it – on trigger. Any Milacron machine can be enhanced with ei3 AI capabilities in less than two weeks. This system will improve equipment productivity and any process ran on the machinery. DATA SECURITY IS KEY Customers can verify without question what data is collected and ei3 is committed to IoT cloud security. All modules provided by the collaboration of Milacron and ei3 are secure: Security of your data is guaranteed from the creation of the machine data, the transfer to the cloud, to the application and any API integration back into the computer system. Strategically placed private data centers leverages physical infrastructure, redundancy, backup, and failover with 24x7 availability to your machine data with no data limits. A rigorous cybersecurity system to constantly monitor and improve applications, systems and processes that withstand the growing risks of cyber hacking. ei3 has attained the ISO 27001 certification of compliance by DEKRA. Orchestrated based on complete admin autonomy, with access to division, machine, completely auditable remote service translations, and module control for unlimited users to receive actionable information on the machine. We invite you to visit us in Hall 1 Booth C05 at the K-Show in Dusseldorf, Germany to see our cutting-edge products and solutions for the plastics processing industry. Milacron continues to push the boundaries of possibilities in plastics with breakthrough products from leading brands including Milacron, Mold-Masters, DME, Ferromatik, TIRAD, and CIMCOOL. About Milacron Milacron is a global leader in the manufacture, distribution, and service of highly engineered and customized systems within the plastic technology and processing industry. Milacron is the only global company with a full-line product portfolio that includes hot runner systems, injection molding, extrusion equipment, auxiliary equipment and a wide market range of advanced fluid technologies. Visit Milacron at www.milacron.com. About ei3 Founded in 1999 ei3 Corporation delivers a suite of applications designed for mid-market manufacturing companies to enjoy the benefits of the Industrial IoT. ei3’s solution increases operational efficiency, saves costs, increase profitability, and enables new business models. Printing presses, injection molding machines, and packaging equipment are some of the market segments led by ei3. ei3 is headquartered in New York with offices in Montreal, Copenhagen and Zurich. Visit ei3 at www.ei3.com. MCRN-IR Contacts Media:Lacy Wise Corporate Communications Manager Lacy_Wise@milacron.comM: +1-513-410-3458 Investor Relations:Bruce Chalmers Milacron, Chief Financial Officer Bruce_Chalmers@milacron.comO: +1-513-319-7985
-
Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, an
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who have one copy of the F508del mutation and another responsive residual function (RF) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. People with CF who have one copy of the F508del mutation and another responsive RF mutation in the CFTR gene will have access to a medicine for the cause of their CF for the first time. In addition, ORKAMBI® (lumacaftor/ivacaftor) is now also reimbursed for the treatment of children with CF ages 2 to 5 who have two copies of the F508del mutation in the CFTR gene. Patients over the age of 6 have already been able to access ORKAMBI® in Australia since October 2018. Following previously received positive recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC), eligible patients in Australia will be able to access both medicines immediately, and the medicines will be listed on the Pharmaceutical Benefits Scheme (PBS) from December 1st. “We are pleased that SYMDEKO® and ORKAMBI® will be made available immediately to eligible cystic fibrosis patients in Australia. We appreciate that the PBAC has recognized the value of these medicines to patients and thank the Department of Health and the Minister for Health in Australia for their strong engagement and collaboration to finalize the agreement,” said Ludovic Fenaux, Senior Vice President, Vertex International. Vertex’s CF medicines are reimbursed in 17 countries around the world including Austria, Denmark, Germany, the Republic of Ireland, Italy, the Netherlands, Sweden and the U.S. About CF Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s. About SYMDEKO® (tezacaftor/ivacaftor) in combination with ivacaftor Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface. Mutations in the CFTR gene, responsive to SYMDEKO®, that are currently registered in Australia include F508del/f and P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, 3849+10kbC→T, E56K, R74W, D110E, D110H, E193K, E831X, F1052V, K1060T, A1067T, F1074L and D1270N. About ORKAMBI® (lumacaftor/ivacaftor) and the F508del mutation In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test. Lumacaftor/ivacaftor is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has three approved medicines that treat the underlying cause of cystic fibrosis (CF) – a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney diseases. Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including nine consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the second and third paragraphs of the press release. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Contacts International Media: +44 20-3204-5275 MediaInfo@vrtx.com +61 4396-03068 matthew.moran@willard.com.au U.S. Media: 617-341-6992 MediaInfo@vrtx.com Investors: 617-961-7163 InvestorInfo@vrtx.com
-
Bragar Eagel & Squire, P.C. is Investigating HEXO Corp. (NYSE: HEXO) on Behalf of Stockholders and Encourages HEXO Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--#HEXO--Bragar Eagel & Squire, P.C. is investigating potential claims against HEXO Corp. (NYSE: HEXO) on behalf of HEXO investors. Our investigation concerns whether HEXO has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 4, 2019, HEXO announced the immediate resignation of its Chief Financial Officer Michael Monahan, after only four months as the Company’s CFO. On this news, HEXO’s stock price fell $0.26 per share, or 6.4%, to close at $3.80 per share on October 7, 2019. Then, on October 10, 2019, HEXO released preliminary revenue results for the fourth quarter of fiscal year 2019 that were nearly 50% lower than previous guidance and withdrew previously announced fiscal year 2020 guidance of up to $400 million in revenue. HEXO’s Chief Executive Officer Sebastien St-Louis attributed these poor results to “lower than expected product sell through” and admitted that the company would have to make “significant changes to our sales and operations strategy to drive future results.” On this news, HEXO’s stock price fell $0.83 per share, or 22.55%, to close at $2.85 per share on October 10, 2019. If you purchased or otherwise acquired HEXO shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into HEXO, please go to https://bespc.com/HEXO. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.comwww.bespc.com
-
Bragar Eagel & Squire, P.C. is Investigating First American Financial Corporation (NYSE: FAF) on Behalf of Stockholders and Encourages First American
NEW YORK--(BUSINESS WIRE)--#firstamerican--Bragar Eagel & Squire, P.C. is investigating potential claims against First American Financial Corporation (NYSE: FAF) on behalf of First American investors. Our investigation concerns whether First American has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 24, 2019, Brian Krebs of krebsonsecurity.com published a report alleging that First American may have allowed unauthorized access to more than 885 million records related to mortgage deals going back to 2003. According to the report, First American said that it learned of a “design defect in one of its production applications that made possible unauthorized access to customer data” and has shut down external access. On this news, First American’s share price fell by more than 6%, closing at $51.80 per share on May 28, 2019. If you purchased or otherwise acquired First American shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into First American, please go to https://bespc.com/FAF. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.comwww.bespc.com
-
Gartner Announces Gartner IT Symposium/Xpo 2019, October 20-24, in Orlando
STAMFORD, Conn.--(BUSINESS WIRE)--Gartner, Inc. (NYSE: IT): What: Gartner IT Symposium/Xpo 2019 When: October 20-24, 2019 Where: Walt Disney World Resort, Orlando, Florida Members of the media can register for the event by contacting katie.costello@gartner.com. Details: Gartner IT Symposium/Xpo 2019 is the world's most important gathering of CIOs and IT executives, enabling more than 9,000 CIOs and senior leaders to shape the future of IT and business strategies. IT Symposium/Xpo brings together a community of IT leaders, technology visionaries and Gartner experts to examine the industry’s most critical trends to help organizations build and execute world-class IT strategies. Over the course of five days, attendees will hear from over 190 Gartner experts and 180 solution providers in 450+ sessions spanning technology & information, leadership and business strategy. Gartner IT Symposium/Xpo Guest Speakers At Gartner IT Symposium/Xpo, join the conversation with these key influencers who will take the stage to provide their unique views on leadership, culture, innovation and digital disruption: Guest Keynotes include: Sir Tim Berners-Lee, Inventor of the World Wide Web Sekou Andrews, Award-winning Poetic Voice, Entrepreneur, and Two-time National Poetry Slam Champion Malcolm Gladwell, New York Times Best-Selling Author and Journalist Jennifer Hyman, Co-Founder and Chief Executive Officer of Rent the Runway CIO Experience Attendees The CIO Experience at Gartner IT Symposium/Xpo is designed to help CIOs focus on their business, technology and leadership development in their enterprises. CIO Experience Guest Speakers include: Jane McGonigal, Director of Game Development & Research, Institute for the Future Chip Conley, Strategic Advisor for Hospitality & Leadership, Airbnb Marc Randolph, Netflix Co-founder, Executive Mentor and Angel Investor This year's agenda delivers more than 450 sessions across three tracks, covering the priorities most critical to CIOs: Business Strategy Leadership Technology & Information These themes will help CIOs and senior IT executives stay ahead of the latest trends including artificial intelligence (AI), data and analytics, security and risk, digital transformation, work, people and culture and more. Sunday Industry Day Industry Day at Gartner IT Symposium/Xpo will be held on Sunday, October 20, with industry-specific sessions and networking opportunities. For the full list of the 9 key sectors covered, please visit the Industry Day agenda. The Sunday Industry Guest Keynote is: Nicole Malachowski, Retired U.S. Air Force Col., First Woman Thunderbird Pilot, Combat Veteran IT Xpo IT Xpo is the solution showcase teeming with leading providers of IT solutions aimed at driving business imperatives. It will highlight the next steps in technology through live demonstrations, face-to-face meetings with exhibitors, and fast-paced presentations on key technology directions aligned with 13 IT Xpo Marketplaces — Applications; Artificial Intelligence & Robotic Process Automation; Customer Experience; Data & Analytics; Digital Business Platforms & Process Management; Digital Workplace; Enterprise Architecture; Enterprise Networking & Communications; IT Infrastructure, Operations & Cloud Strategies; Mobility & Wireless, Program & Portfolio Management; Security & Risk Management; Sourcing & IT Services— as well as Emerging Technology vendors and Industry Day Communication Walls. For complete event and registration details, please visit Gartner IT Symposium/Xpo 2019. Follow news and updates from the event on social media using #GartnerSYM. About Gartner Gartner, Inc. (NYSE: IT) is the world’s leading research and advisory company and a member of the S&P 500. We equip business leaders with indispensable insights, advice and tools to achieve their mission-critical priorities and build the successful organizations of tomorrow. Our unmatched combination of expert-led, practitioner-sourced and data-driven research steers clients toward the right decisions on the issues that matter most. We are a trusted advisor and objective resource for more than 15,000 organizations in more than 100 countries — across all major functions, in every industry and organization size. To learn more about how we help decision makers fuel the future of business, visit www.gartner.com. Contacts Katie Costello Gartner 571 444 1091 katie.costello@gartner.com
-
ASM Introduces Blockchain-based Checksome™ to Accelerate Credentialing and Advance Patient Safety
TEMECULA, Calif.--(BUSINESS WIRE)--Applied Statistics & Management, Inc. (ASM) introduces Checksome™, a blockchain-based technology, that contains nearly two million primary source verifications that are encrypted and secured by the blockchain. This data is critical for reducing credentialing processing times, while also providing proactive notifications for licensure changes. Checksome™ is available to all MD-Staff customers free of charge. MD-Staff is a cloud-based, AI-enabled, and user-friendly credentialing software solution backed by 30 years of innovation. Traditionally, there is a lot of duplicated credentialing work because each individual organization is independently verifying each practitioner’s licenses and credentials. Additionally, as practitioners are onboarded with different organizations, they must continually provide the same information to each. Checksome™ aims to solve this problem by providing a single, secure data repository using blockchain technology. “Checksome™ allows our customers to accelerate credentialing times, while allowing them to more proactively monitor their medical staff,” said Nick Phan, Executive Vice President of ASM. “Blockchain technology provides the security and trust required, while also eliminating duplicate work.” To learn more about Checksome™, visit ASM at booth #511 at the 2019 NAMSS Conference or contact the ASM sales team at https://www.mdstaff.com. About ASM Applied Statistics & Management, Inc. (ASM) empowers healthcare organizations to advance patient safety and quality objectives using cloud-based, AI-enabled software solutions. Over 1,200 facilities worldwide use ASM products—MD-Staff and MD-Stat—to automate and manage their credentialing, privileging, OPPE, FPPE, and peer review processes. To learn more, visit www.mdstaff.com. Contacts Celena Barton cbarton@mdstaff.com
-
GEICO Says: Pack Your Patience; Put Safety First While Driving in Parking Lots
WASHINGTON--(BUSINESS WIRE)--Whether it’s a few spaces outside a small shop or a large multi-level garage, GEICO urges drivers to remain patient and stay alert while driving through parking lots. Parking lot safe-driving plan: Stick to low speeds: At any moment, a car could back out of a spot or a pedestrian could try to cross. Drivers need to proceed slowly so they have enough time to react in case one of these common scenarios occurs. Always remember to look back: Even if you’re driving a vehicle equipped with a backup camera, you should still look back from the driver’s seat to scan your surroundings. Drivers should treat technology like backup cameras and their accompanying traffic alert sensors as additional tools to help them see more of what’s around them. Stay mindful of pedestrians: Parking lots have both high volumes of vehicle and foot traffic. Drivers should always stop to let pedestrians cross the street, whether at a crosswalk or elsewhere. Drivers also need to make extra effort to monitor the area around them so they don’t miss someone stepping out from in between vehicles for example. Get situated while you’re parked: If you need to reply to a text or email, stream music or set a new GPS destination, take care of that while you’re still sitting in the parking space. These activities can lead to a driver becoming distracted once the car is moving. Lock up: After exiting your vehicle, always remember to lock all the doors. An unlocked car provides a prime opportunity for thieves, no matter where it’s parked. Also, consider covering up valuable items or storing them out of sight in the trunk or another compartment within your vehicle. For more safe driving tips, visit the car safety and insurance page on GEICO More. GEICO (Government Employees Insurance Company), the second-largest auto insurer in the U.S., was founded in 1936 and insures more than 28 million vehicles. For more than 80 years, the company has worked to make people’s lives better by protecting policyholders against unexpected events. As GEICO has grown, it has delivered money-saving coverage and outstanding customer service to policyholders through its investment in human resources and technology. GEICO is a member of the Berkshire Hathaway family of companies. Contacts GEICO Communications gcorpcomm@geico.comTo view GEICO's Blog: https://www.geico.com/more/
